 This is a randomized, double-blind, single-dose, 2-period crossover study in healthy subjects to assess PK, PD, and safety including immunogenicity of a single 6 mg subcutaneous SC injection of CHS-1701 compared with a single 6 mg SC dose of Neulasta. 